These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 16618270

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Blood pressure reduction with olmesartan in mild-to-moderate essential hypertension: a planned interim analysis of an open label sub-study in German patients.
    Böhm M, Ewald S, Olmebest Study Authors.
    Curr Med Res Opin; 2006 Jul; 22(7):1375-80. PubMed ID: 16834836
    [Abstract] [Full Text] [Related]

  • 5. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study.
    Aurora SK, Gawel M, Brandes JL, Pokta S, Vandenburgh AM, BOTOX North American Episodic Migraine Study Group.
    Headache; 2007 Apr; 47(4):486-99. PubMed ID: 17445098
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Montelukast for migraine prophylaxis: a randomized, double-blind, placebo-controlled study.
    Brandes JL, Visser WH, Farmer MV, Schuhl AL, Malbecq W, Vrijens F, Lines CR, Reines SA, Protocol 125 study group.
    Headache; 2004 Jun; 44(6):581-6. PubMed ID: 15186302
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A randomized, double blind, placebo-controlled study of MAP0004 in adult patients with migraine.
    Aurora SK, Rozen TD, Kori SH, Shrewsbury SB.
    Headache; 2009 Jun; 49(6):826-37. PubMed ID: 19545249
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of 6.25 mg t.i.d. feverfew CO2-extract (MIG-99) in migraine prevention--a randomized, double-blind, multicentre, placebo-controlled study.
    Diener HC, Pfaffenrath V, Schnitker J, Friede M, Henneicke-von Zepelin HH.
    Cephalalgia; 2005 Nov; 25(11):1031-41. PubMed ID: 16232154
    [Abstract] [Full Text] [Related]

  • 17. Early intervention with almotriptan: results of the AEGIS trial (AXERT Early Migraine Intervention Study).
    Mathew NT, Finlayson G, Smith TR, Cady RK, Adelman J, Mao L, Wright P, Greenberg SJ, AEGIS Investigator Study Group.
    Headache; 2007 Feb; 47(2):189-98. PubMed ID: 17300358
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.